단장증후군 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of short bowel syndrome (SBS) Market

The global short bowel syndrome (SBS) market is witnessing steady growth, driven by rising disease prevalence, increasing adoption of advanced therapies, and growing awareness of rare gastrointestinal disorders. The market size was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.89 billion in 2026, reaching USD 2.7 billion by 2034, registering a CAGR of 4.57% during 2026-2034.

North America dominated the global market with a 75.87% share in 2025, supported by a large diagnosed patient pool, strong reimbursement systems, and high adoption of innovative therapies. The U.S. market is a key contributor, projected to reach USD 1.93 billion by 2032.

Market Dynamics

Short bowel syndrome is a rare condition associated with intestinal failure, where patients rely heavily on parenteral support (PS) for nutrients. Globally, around 15,000-20,000 patients in the U.S. and EU-5 are affected. However, long-term dependence on parenteral nutrition leads to complications such as liver dysfunction and infections, along with high annual treatment costs ranging from USD 65,000 to USD 320,000.

This has increased the demand for advanced drug therapies, particularly GLP-2 analogs, which enhance intestinal absorption and reduce dependency on parenteral nutrition. Currently, Gattex (Revestive) by Takeda Pharmaceutical Company Limited is the only approved GLP-2 drug, although several pipeline candidates are under development.

Market Trends

A key trend shaping the market is the shift from total parenteral nutrition (TPN) to GLP-2-based therapies. These drugs offer improved patient outcomes, reduced hospitalization, and better quality of life.

Pharmaceutical companies are actively investing in clinical trials. For instance, Zealand Pharma A/S reported positive Phase 3 results for Glepaglutide, a long-acting GLP-2 analog. Similarly, Hanmi Pharm Co., Ltd. is advancing its GLP-2 pipeline candidate.

Market Growth Drivers

Increasing Adoption of GLP-2 Drugs

The penetration of GLP-2 therapies is rising significantly, especially in developed markets such as the U.S. and Europe. Around 18-20% of SBS patients in the U.S. are already treated using these drugs. Their ability to reduce parenteral support dependency is a major growth driver.

Rising Awareness and Support Programs

Organizations such as patient foundations and healthcare bodies are promoting awareness and education regarding SBS. This is improving diagnosis rates and treatment adoption globally.

Growing R&D Investments

Companies like Ironwood Pharmaceuticals are investing heavily in research to develop next-generation therapies, further supporting market expansion.

Restraining Factors

Despite positive growth, the market faces challenges due to high treatment costs. The annual cost of GLP-2 drugs such as Gattex can range between USD 200,000 and USD 300,000 per patient, limiting accessibility in developing regions.

Additionally, limited reimbursement policies and low awareness in countries such as India and parts of Africa restrict market penetration.

Segmentation Analysis

By Type

The GLP-2 segment dominated the market in 2026, accounting for 97.01% share, due to the availability of approved drugs and strong pipeline development. Other segments include growth hormone and glutamine therapies.

By Distribution Channel

The online & retail pharmacy segment led the market with a 60.66% share in 2026, driven by increasing digital adoption and easy accessibility of medications.

Regional Insights

North America

North America led the market with USD 1.25 billion in 2025 and is expected to reach USD 1.45 billion in 2026. Growth is driven by advanced healthcare infrastructure and high adoption of innovative therapies.

Europe

Europe accounted for USD 0.18 billion in 2025, supported by strong clinical research and favorable treatment guidelines.

Asia Pacific

Asia Pacific recorded USD 0.17 billion in 2025 and is expected to grow steadily due to rising awareness and increasing clinical trials.

Latin America & Middle East & Africa

These regions show gradual growth due to improving healthcare access and increasing awareness of rare diseases.

Competitive Landscape

The market is highly concentrated, with Takeda Pharmaceutical Company Limited leading due to its strong product portfolio. Other key players include Zealand Pharma A/S, Ironwood Pharmaceuticals, Merck KGaA, and Nestle Health Science.

These companies are focusing on collaborations, clinical trials, and innovative drug development to strengthen their market position.

Conclusion

In conclusion, the short bowel syndrome market is poised for steady growth, rising from USD 1.65 billion in 2025 to USD 2.7 billion by 2034. The increasing adoption of GLP-2 therapies, growing awareness, and strong R&D investments are key factors driving this expansion. However, high treatment costs and limited access in developing regions remain significant challenges. Overall, advancements in drug innovation and expanding clinical pipelines are expected to enhance treatment outcomes and create new growth opportunities in the coming years.

Segmentation By Type

• GLP-2
• Growth Hormone
• Glutamine

By Distribution Channel

• Hospital Pharmacies
• Online & Retail Pharmacies

By Region

• North America (By Type, By Distribution Channel, By Country)
  • U.S.
  • Canada
• Europe (By Type, By Distribution Channel, By Country/Sub-Region)
  • Germany
  • U.K
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Type, By Distribution Channel, By Country/Sub-Region)
  • India
  • China
  • Japan
  • Australia
  • Southeast Asia
  • South Korea
  • Rest of Asia Pacific
• Latin America (By Type, By Distribution Channel, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America
• Middle East & Africa (By Type, By Distribution Channel, By Country/Sub-Region)
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Short Bowel Syndrome, By Key Countries, 2025
• 4.2. Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
• 4.3. Impact of COVID-19 on the Global Market

5. Global Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. GLP-2
  • 5.1.2. Growth Hormone
  • 5.1.3. Glutamine
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacies
  • 5.2.2. Online & Retail Pharmacies
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. GLP-2
  • 6.1.2. Growth Hormone
  • 6.1.3. Glutamine
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Online & Retail Pharmacies
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. GLP-2
  • 7.1.2. Growth Hormone
  • 7.1.3. Glutamine
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Online & Retail Pharmacies
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Rest of Europe

8. Asia Pacific Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. GLP-2
  • 8.1.2. Growth Hormone
  • 8.1.3. Glutamine
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Online & Retail Pharmacies
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
  • 8.3.2. South Korea
  • 8.3.3. Australia
  • 8.3.4. China
  • 8.3.5. India
  • 8.3.6. Southeast Asia
  • 8.3.7. Rest of Asia Pacific

9. Latin America Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. GLP-2
  • 9.1.2. Growth Hormone
  • 9.1.3. Glutamine
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacies
  • 9.2.2. Online & Retail Pharmacies
• 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Argentina
  • 9.3.4. Colombia
  • 9.3.5. Rest of Latin America

10. Middle East & Africa Short Bowel Syndrome Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. GLP-2
  • 10.1.2. Growth Hormone
  • 10.1.3. Glutamine
• 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.2.1. Hospital Pharmacies
  • 10.2.2. Online & Retail Pharmacies
• 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.3.1. Turkey
  • 10.3.2. Saudi Arabia
  • 10.3.3. UAE
  • 10.3.4. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Takeda Pharmaceutical Company Limited
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Merck KGaA
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. ZEALAND PHARMA
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Ironwood
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Hanmi Pharm. Co., Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Nestle
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Jaguar Health
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. EnteraBio Ltd.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. OxThera
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)